Hosted on MSN11d
Atsena’s ATSN-201 gains FDA fast track status for XLRS treatment
Atsena Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for its gene therapy ...
Healio12d
FDA grants fast track designation to X-linked retinoschisis treatment
The FDA granted fast track designation to ATSN-201 for the treatment of X-linked retinoschisis, according to a press release ...
Healthline8d
What to Know About Juvenile Macular Degeneration (JMD)
The three main types of juvenile macular degeneration (JMD) include Stargardt disease, X-linked retinoschisis, and Best disease. These result from gene mutations. Early treatment may help preserve ...
Business Insider12d
Atsena Therapeutics Granted U.S. FDA Fast Track Designation for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis
Enrollment for this study is ongoing. For more information, visit ClinicalTrials.gov (Identifier: NCT05878860). About X-linked Retinoschisis (XLRS) XLRS is a monogenic X-linked disease caused by ...
Morningstar12d
Atsena Therapeutics Granted U.S. FDA Fast Track Designation for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis
has granted Fast Track designation for ATSN-201 for the treatment of X-linked retinoschisis (XLRS). ATSN-201, a best-in-class gene therapy product candidate, leverages AAV.SPR, the company’s ...
manilatimes13d
Atsena Therapeutics Granted U.S. FDA Fast Track Designation for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis
has granted Fast Track designation for ATSN-201 for the treatment of X-linked retinoschisis (XLRS). ATSN-201, a best-in-class gene therapy product candidate, leverages AAV.SPR, the company's novel ...